MedTrace Logo

Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History

NCT05867381 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2025-08-01

No results posted yet for this study

Summary

This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.

Conditions

Interventions

DEVICE

HEPA filtration

HEPA filters with the capacity to reduce PM2.5 levels

DEVICE

Sham filtration

Sham filtration use the same appearance of air purifier but with HEPA filter removed.

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • National Institute of Environmental Health Sciences (NIEHS)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Zhanghua Chen, PhD · University of Southern California

  • Junfeng Zhang, PhD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
65 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-11
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05867381 on ClinicalTrials.gov